NCT00780858

Premature Luteinization Prevention by GnRH Antagonist in Patients Undergoing IUI

GnRH Antagonist Prevention of Premature Luteinization in Patients Undergoing IUI

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 662 (actual)
• Sponsor: IVI Madrid · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Premature luteinization in patients undergoing IUI can occur in up to 24% of cycles. These patients, according to recent data, have a lower pregnancy rate than controls. The possibility to avoid premature luteinization with GnRH antagonist may restore the chances of achieving a pregnancy in these women.

Detailed description

The purpose of this study was to investigate whether a subset of patients benefits from GnRHa administration during IUI. PL was tested for in patients who were undergoing artificial insemination procedures, and the effect of GnRHa on PR in patients who

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	Ganirelix	Ganirelix 0.25mg s.c every 24 h starting stimulation day 6

Timeline

• Start date: 2008-10-01
• Primary completion: 2010-12-01
• Completion: 2011-03-01
• First posted: 2008-10-28
• Last updated: 2015-05-06

Locations

1 site across 1 country: Spain